Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMar 8, 2023Daptomycin for Injection 350 mg/vialCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0381-2023Class IITerminatedMar 8, 2023Clopidogrel Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0380-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 30 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0379-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0378-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 15 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0377-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0376-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 7.5 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0375-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 80 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0374-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 40 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0373-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 20 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0372-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0371-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0370-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0369-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0368-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0367-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0366-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0365-2023Class IITerminatedMar 8, 2023Sterile Water for InjectionCGMP Deviations: Potential product carryover.Nephron Sc Inc · D-0364-2023Class IIITerminatedMar 8, 2023Fentanyl 1Subpotent DrugSCA Pharmaceuticals · D-0363-2023Class IITerminatedMar 8, 2023Phenylephrine HCl in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0362-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0361-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0360-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0359-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0358-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0357-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0356-2023Class IITerminatedMar 8, 2023Diltiazem HCl in 0.7% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0355-2023Class IIITerminatedMar 8, 2023Gabapentin TabletsPresence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.Sciegen Pharmaceuticals Inc · D-0354-2023Class IITerminatedMar 8, 2023Levothyroxine Sodium TabletsSub-Potent Drug: Out of specification for assay at the 24 month interval.Alvogen, Inc · D-0353-2023Class IIITerminatedMar 8, 2023BD-102 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0352-2023Class IIITerminatedMar 8, 2023Avicel PH-200 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0351-2023Class IIITerminatedMar 8, 2023Avicel PH- 102 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0350-2023Class IIITerminatedMar 8, 2023Avicel PH- 101 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0349-2023Class IITerminatedMar 1, 2023Warfarin Sodium TabletsFailed Impurities/Degradation SpecificationsRising Pharmaceuticals · D-0348-2023Class IICompletedMar 1, 20230.9% Sodium Chloride InjectionLack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an...B. Braun Medical Inc. · D-0347-2023Class IICompletedMar 1, 20230.9% Sodium Chloride InjectionLack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an...B. Braun Medical Inc. · D-0346-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0345-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0344-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0343-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0342-2023